ライフサイエンスコーパス: haematology

1 German Association of Pediatric Oncology and Haematology.

2 at the juncture of cardiology, oncology and haematology.

3 val of race-based reference intervals across haematology.

4 into the research and practice landscape of haematology.

5 gy, non-malignant haematology, and classical haematology.

6 th in chronic hypoxia, but had no effects on haematology.

7 ons for both basic HSC research and clinical haematology.

8 ) and the British Committee for Standards in Haematology (2003), issues surrounding the diagnosis and

9 Histology, haematology and biochemical analysis of urine and plasma

10 idered the effect of adjusting for 15 common haematology and biochemistry test results or proxies for

11 15 routine haematology and biochemistry test results were highly pr

12 nt defined clinically or by changes in blood haematology and biochemistry variables, measured monthly

13 ive SARS-CoV-2 antibody and PCR test, normal haematology and chemistry panels, a normal electrocardio

14 The haematology and oncology specialty had the highest repre

15 titute of Pathology/Department of Paediatric Haematology and Oncology, Hannover Medical School) from

16 combination therapies across the spectra of haematology and oncology, highlighting opportunities for

17 he inclusion of radiation oncology alongside haematology and oncology, pathology and molecular biolog

18 tested for viraemia, undertook analyses for haematology and serum biochemistry, and measured humoral

19 oups exhibited negative correlations between haematology and TF biomarkers with inflammation and orga

20 laboratory analytes (ie, serum chemistry and haematology), and participant incidence of denosumab ant

21 rred to as benign haematology, non-malignant haematology, and classical haematology.

22 lected blood samples for clinical chemistry, haematology, and filovirus antibodies using ELISA.

23 Participants were from medical, surgical, haematology, and oncology units.

24 e German Society for Paediatric Oncology and Haematology, and the Japanese Study Group for Paediatric

25 In haematology, as in all of medicine, the use of reference

26 Consequently, the European Haematology Association commissioned experts in the fiel

27 (ASH) and British Committee for Standards in Haematology (BCSH) guidelines indicate that at platelet

28 Haematology, biochemistry, and CD4-cell counts were done

29 d by 12-lead electrocardiogram; vital signs; haematology, biochemistry, and urinalysis; rice protein-

30 g vital signs, cardiovascular profile, serum haematology, biochemistry, urinalysis, PSA, and Adverse

31 dence of advanced disease including abnormal haematology, blood chemistry and coagulopathy, siRNA-tre

32 ry variables, including lipid panel, routine haematology, blood chemistry, urinalysis, coagulation, a

33 more uniform adoption of the term classical haematology by organisations, academic divisions, and cl

34 s) patients who received medical oncology or haematology care in a US multi-state health system were

35 -containing salvage therapy from 12 oncology-haematology centres in Italy.

36 e cell anaemia in steady state attending the Haematology clinic of a federal tertiary health institut

37 el-group, randomised trial in secondary-care haematology clinics in 11 UK hospitals.

38 assigned 15 clusters of medical oncology and haematology clinics in the USA sharing a common EHR, Epi

39 ne in 210 centres (including community-based haematology clinics, major hospitals, and academic insti

40 porting Series, a follow-up of a 2018 Lancet Haematology Commission, we review advances in the report

41 key actions that we feel are crucial for the haematology community to pursue to abrogate systemic rac

42 and 15 retrospective studies, drawn from 14 haematology conference abstracts and 19 full text articl

43 ere scored daily and blood was collected for haematology counts, until euthanasia at day 7 post-chall

44 Unlike the alternatives, the term classical haematology evokes the field's rich, centuries-long hist

45 ractice guidelines by the British Paediatric Haematology Group in 1992 and by the American Society of

46 ology and British Committee for Standards in Haematology guidelines for the diagnosis and management

47 atrics, laboratory and transfusion medicine, haematology, health technology assessments, and populati

48 d the effect of treatment on body condition, haematology, immune function, physiological stress and o

49 vided by cumulative burden in controls) were haematology, immunology/infection and pulmonary conditio

50 nd the editorial boards of seven high-impact haematology journals, with under-representation of radia

51 od cancers is variably referred to as benign haematology, non-malignant haematology, and classical ha

52 nt cohorts: the Nordic Society of Paediatric Haematology (NOPHO) ALL2008 T-ALL study cohort (n = 192)

53 The entirety of haematology not involving blood cancers is variably refe

54 experts in the field of infectious diseases, haematology, oncology, clinical pharmacology, and method

55 nternational panel of experts in nephrology, haematology, oncology, nephropathology, critical care, p

56 surable residual disease (MRD) assays across haematology-oncology creates an urgent need for clinicia

57 us Disease Unit (AMU/IDU), Pre-surgical, and Haematology-Oncology departments were screened.

58 nd 577 (95% Credible Interval: 370, 633) for haematology-oncology patients to pound 2329 (947, 19,504

59 p<0.0001), not having a separate paediatric haematology-oncology unit (1.38 [1.21-1.57]; p<0.0001),

60 lly examine two premises behind MRD's use in haematology-oncology, focusing on its biological plausib

61 ccordingly, a group of experts in paediatric haematology-oncology, representative of 17 international

62 undetectable MRD seems an attractive goal in haematology-oncology, we highlight the epistemic limitat

63 ranging from 37% in renal/transplant, 29% in haematology/oncology, and 28% in acute/elderly medicine

64 We prospectively identified and followed 149 haematology patients admitted to a hospital in England f

65 ted findings are very common in oncology and haematology patients.

66 German Association of Pediatric Oncology and Haematology pediatric cooperative groups, important vari

67 ical practice, with oncology, immunology and haematology poised for initial adoption.

68 g a multi-resource approach (PCR, histology, haematology, population genetics, eDNA), we identified 1

69 ened an international panel of 26 experts in haematology, primary care, paediatrics, obstetrics, gast

70 Greatest divergence in haematology profile was observed between Ctl-In vs VitD-

71 t feeding, clinical status, and biochemistry/haematology results were collected in a separate infant

72 rsity of New South Wales, Monash University, Haematology Society of Australia and New Zealand, Leukae

73 The haematology-specific version ESMO-MCBS:H allows now full

74 erential use of alternative biochemistry and haematology tests by clinicians, diagnosis by malaria co

75 e encountered when addressing vaccination in haematology: the small size of the cohorts that makes it

76 We measured iron biomarkers and haematology traits on individuals participating in the K

77 y-phase trials, novel PRO-based endpoints in haematology trials, and updated PRO measures that reflec

78 inly clinical trial endpoints that differ in haematology versus solid oncology and the very indolent

79 tered ePROMs in association with oncology or haematology visits.

80 have a common programme for vaccination in a haematology ward.

81 t study, patients were admitted to two adult haematology wards at the Cambridge University Hospitals

82 li positive blood samples from the two adult haematology wards.

83 from use of adult haemopoietic stem cells in haematology will facilitate and hasten transition from l